Koichi Goto
Leads thoracic oncology at NCC East and the LC-SCRUM-Japan network that connects rare-driver lung cancer patients to trials.
Koichi Goto has led Japanese and global trials of RET, ROS1, MET, and HER2 inhibitors in NSCLC and directs the clinical side of LC-SCRUM-Japan, one of the largest genomic screening efforts in lung cancer.
Pages like this
not linked directly; found by shared links- PersonAlexander Drilon
Shares Selpercatinib, ROS1, RET, Non-small-cell lung cancer.
- PersonToshihiko Doi
Shares National Cancer Center Hospital East, National Cancer Center Hospital, Trastuzumab deruxtecan.
- PersonTakashi Kohno
Shares RET, National Cancer Center Hospital, Non-small-cell lung cancer.
- TrialLIBRETTO-431
Shares Selpercatinib, RET, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares Selpercatinib, ROS1, RET, Non-small-cell lung cancer.
- ProductPralsetinib
Shares Selpercatinib, RET, Non-small-cell lung cancer.
- PersonBob T. Li
Shares Trastuzumab deruxtecan, HER2, Non-small-cell lung cancer.
- PersonKohei Shitara
Shares National Cancer Center Hospital East, National Cancer Center Hospital, Trastuzumab deruxtecan, HER2.